EGI
KIN

EAM Global Investors’s Kindred Biosciences, Inc. KIN Stock Holding History

EAM Global Investors’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-96,808
Closed -$1.06M – 175
2018
Q4 		$1.06M Hold
96,808
– – 0.58% 92
2018
Q3 		$1.35M Buy
+96,808
New +$1.31M 0.55% 94

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

EAM Global Investors's KIN Position: Q1 2019 in Review

EAM Global Investors sold out of Kindred Biosciences, Inc. (KIN) in Q1 2019, closing a stake of 96,808 shares — an estimated $1.06M sold.

EAM Global Investors first reported a position in KIN in Q3 2018 and held it in 2 quarters. The position peaked at $1.35M in Q3 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q1 2019.

  • EAM Global Investors reported no remaining Kindred Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
  • EAM Global Investors sold 96,808 Kindred Biosciences, Inc. shares in Q1 2019, an estimated $1.06M.
  • EAM Global Investors first reported a position in Kindred Biosciences, Inc. in Q3 2018 and held it in 2 quarters.
  • EAM Global Investors's Kindred Biosciences, Inc. position peaked at $1.35M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2019.

Based on EAM Global Investors's 13F filing for Q1 2019, filed 10 May 2019.